New Service: Alicanto for Antibody Discovery from Human Serum
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!
Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!
Click below to watch the presentation.
Related Posts
Monoclonal versus Polyclonal Antibody Sequencing
Antibody reagents used in biomedical research and diagnostics assays fall into two large categories: monoclonals and polyclonals. For high-quality reagents, an antibody needs to demonstrate specific reactivity in its intended assay, and maintain consistency across...
Polyclonal Antibody Sequencing Methods
Polyclonal Antibody Sequencing Methods Polyclonal antibody sequencing is a powerful tool for understanding the humoral immune response.1 Two primary approaches exist: Proteogenomic Polyclonal Antibody Sequencing and De Novo Polyclonal Antibody Sequencing. This guide...
Griffin: Accessing functional antibodies from serum without B cells
Griffin is a platform for sequencing polyclonal antibodies using mass spectrometry. Since 2009, Abterra Biosciences founders and employees have been developing novel methods for sequencing antibody proteins directly. Our monoclonal antibody sequencing service,...
Get In Touch